TMCI

TREACE MEDICAL CONCEPTS INC

Healthcare | Micro Cap

-$0.23

EPS Forecast

$48.41

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Treace Medical Concepts Q3 2026: Lapiplasty Momentum Underpins Growth, Cash Burn Slows as The Company Counts on New Technologies

Overview at a glance

Treace Medical Concepts, Inc. (TMCI) released its third-quarter 2026 results, painting a picture of momentum in its core bunion portfolio even as the top line faces the usual profitability math of a growth-stage medical device company. The company reported revenue of $48.3 million for the quarter, a net loss of $12.6 million, and an Adjusted EBITDA of $0.3 million. Notably, the press release does not provide an EPS figure or a revenue forecast within this excerpt, so investors will be left weighing EPS consensus against the reported numbers to gauge whether there was an earnings surprise or a miss. The update also highlights reduced cash usage and a sharpened focus on a broader product slate built around Lapiplasty and related technologies.

Recent highlights

  • Revenue performance: Generated $48.3 million in Q3 2026.
  • Bottom-line dynamics: Improved third-quarter net loss by 23% to $(12.6) million; Adjusted EBITDA rose to $0.3 million year over year.
  • Cash discipline: Reduced year-to-date cash usage by 53% versus the prior year, with cash, cash equivalents, and marketable securities totaling $39.8 million as of September 30, 2026.
  • Clinical validation: Announced 5-year results of a prospective multicenter study demonstrating long-term, positive outcomes of the Lapiplasty® procedure—an industry milestone for a commercial instrumented bunion correction system.
  • Adoption tailwinds: Approximately 45% of Lapiplasty surgeon users are incorporating one or more of the three new bunion systems launched in Q3 2025, up from 40% in Q2 2026.
  • Product portfolio: Continued adoption of an expanded bunion portfolio, with reference to the SuperBite® compression screws as part of the technology mix.
  • Leadership commentary: CEO John T. Treace underscored disciplined investments in growth initiatives, a focus on profitability, and efforts to finish the year with momentum.

What the numbers are telling a strategist

The quarter reads as a mid-cycle, high-signal story: a sizable, recurring revenue stream from Lapiplasty-related procedures, with accelerating adoption of the newer bunion systems and a richer product ecosystem designed to expand the company’s addressable market. The absence of a disclosed EPS figure and a formal revenue forecast in the release invites market participants to map the reported results against expectations in a broader framework—specifically, the EPS consensus and the potential for an earnings surprise, given the company’s trajectory and cost discipline.

The improvement in net loss, even as revenue remains modest relative to a fully mature medical device company, highlights leverage in operating costs and the impact of strategic mix shifts—toward higher-value, instrumented procedures and a broader portfolio. The cash burn moderation, reflected in a 53% year-over-year reduction, supports a narrative that Treace can sustain more aggressive R&D and commercial investments without an unsustainable liquidity trajectory—an important note for investors sizing the company’s runway.

Strategic implications for Treace and peers

The durable news here is the momentum around Lapiplasty and the expansion of the bunion portfolio, including the introduction of new systems and the continued push of SuperBite compression screws. For Treace, the path remains clear: translate early clinical validation into broader surgeon adoption, convert that adoption into higher utilization per surgeon, and monetize the portfolio through a mix of capital-efficient devices and consumables. The 5-year prospective multicenter study results provide a rare form of medical-device validation that can support premium pricing, higher adoption among surgeons, and potential opportunities for international expansion down the line.

From a sector perspective, peers in perioperative and foot-and-ankle platforms should watch for Treace’s ability to scale its newer Bunion Systems and to sustain the positive cash-flow trajectory as the procedural mix shifts toward instrumented solutions. If these trends persist, the broader market could see increased attention on product development cycles that couple new hardware with complementary disposables and implants—often a kill-switch for adoption velocity in specialty orthopedic segments.

Outlook and what to watch next

Key questions for the next reports include: Will Treace publish a formal revenue forecast and a more explicit EPS metric to anchor expectations against EPS consensus? Can the company sustain its cash-dilution moderation while continuing to invest in the product pipeline, particularly around SuperBite screws and the expanded bunion portfolio? And how will the ongoing 5-year study results translate into real-world adoption and payer acceptance?

For sector peers, the takeaways are practical: validation through robust, long-term studies can move the needle on surgeon confidence and hospital procurement decisions. A diversified product line that reduces reliance on a single revenue source can help weather competitive pressures and macro twists in the healthcare market.

Bottom line

Treace’s Q3 2026 results deliver a narrative of momentum supported by ongoing clinical validation and a growing ecosystem around Lapiplasty. The company’s ability to convert new products into recurring demand, along with disciplined cash management, positions TMCI to extend its lead in the bunion correction space. While the topline remains a work in progress, the strategic shifts—broader adoption, product expansion, and evidence generation—offer a path toward stronger profitability and longer-term earnings power. In the world of EPS and revenue forecasts, Treace is betting that more doctors will line up for a broader suite of bunion solutions, and that the market will reward that line extension with steadier cash generation and a clearer path to durable growth.